A Study of the Use of Quantiferon CMV Blood Test to Find the Length of CMV Prevention in CMV Donor (+) / Recipient (-) Solid Organ Transplant Recipients


About this study

The overall aim of this study is to evaluate the clinical utility of the QuantiFERON-CMV test in solid organ transplant recipients on CMV prophylaxis to predict development of CMV disease after completion of prophylaxis. Our hypothesis is that in CMV D+/R- solid organ transplant recipients, the development of immunity as measured by a positive QuantiFERON CMV assay will predict a lower risk of CMV disease after prophylaxis is completed.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

  • Patients 18 years old or older that will receive a solid organ transplant at Mayo Clinic

  • Participants (recipients) must be negative for CMV serology prior to transplant.

  • Donor must be seropositive for CMV

  • Patients that give us consent to be enrolled in our study and to obtain a sample of blood for QuantiFERON-CMV testing, at the above mentioned points in time.

Exclusion criteria:

  • Lack of informed consent


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Raymund Razonable, M.D.

Closed for enrollment

Contact information:

Maria Dioverti Prono M.D.

(507) 284-3747


More information


Publications are currently not available